Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 3/20 | 0.42 |
| ▸ | MAPK3 | P27361 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.40 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.40 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.40 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.40 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1847759 | 0.82 | BRAF (0.40) | BRAFMAPK3MAPK1MAPK13CSNK1D | |
| SCHEMBL10216183 | 0.81 | BRAF (0.42) | BRAFMAPK3MAPK1MAPK13CSNK1D | |
| SCHEMBL27908263 | 0.76 | BRAF (0.36) | BRAFMAPK3MAPK1MAPK13CSNK1D | |
| SCHEMBL12491353 | 0.75 | BRAF (0.53) | BRAFMAPK3MAPK1CSNK1DCSNK1E | |
| SCHEMBL15192238 | 0.73 | CYP17A1 (0.40) | BRAFMAPK3MAPK1 | |
| SCHEMBL15192043 | 0.73 | PIK3CA (0.43) | BRAFIMPDH2JAK2 | |
| SCHEMBL27908264 | 0.73 | BRAF (0.40) | BRAFMAPK3MAPK1MAPK13CSNK1D | |
| SCHEMBL31111773 | 0.73 | PDE10A (0.37) | MAPK13CSNK1DCSNK1EMAPK12MAPK11 | |
| SCHEMBL574898 | 0.73 | BRD4 (0.45) | BRAFIMPDH2 | |
| SCHEMBL2050662 | 0.72 | BRAF (0.44) | BRAFMAPK3MAPK1MAPK13CSNK1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103153980-B | Derivatives of pyrazolophenylbenzenesulfonamide compounds and their use as antitumor agents | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-12-16 | — | — | CN | disclosed |
| EP-2601185-B1 | DERIVATIVES OF PYRAZOLOPHENYL-BENZENESULFONAMIDE COMPOUNDS AND USE THEREOF AS ANTITUMOR AGENTS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2015-10-07 | — | — | EP | disclosed |
| EP-2601185-B1 | DERIVATIVES OF PYRAZOLOPHENYL-BENZENESULFONAMIDE COMPOUNDS AND USE THEREOF AS ANTITUMOR AGENTS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2015-10-07 | — | — | EP | disclosed |
| US-9114137-B2 | Derivatives of pyrazolophenyl-benzenesulfonamide compounds and use thereof as antitumor agents | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-08-25 | — | — | US | disclosed |
| US-9114137-B2 | Derivatives of pyrazolophenyl-benzenesulfonamide compounds and use thereof as antitumor agents | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-08-25 | — | — | US | disclosed |
| US-9114137-B2 | Derivatives of pyrazolophenyl-benzenesulfonamide compounds and use thereof as antitumor agents | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-08-25 | — | — | US | disclosed |
| US-20130217715-A1 | DERIVATIVES OF PYRAZOLOPHENYL-BENZENESULFONAMIDE COMPOUNDS AND USE THEREOF AS ANTITUMOR AGENTS | LSI FINANCING 1 DESIGNATED ACTIVITY COMPANY (IE) | 2013-08-22 | — | — | US | disclosed |
| US-20130217715-A1 | DERIVATIVES OF PYRAZOLOPHENYL-BENZENESULFONAMIDE COMPOUNDS AND USE THEREOF AS ANTITUMOR AGENTS | LSI FINANCING 1 DESIGNATED ACTIVITY COMPANY (IE) | 2013-08-22 | — | — | US | disclosed |
| US-20130217715-A1 | DERIVATIVES OF PYRAZOLOPHENYL-BENZENESULFONAMIDE COMPOUNDS AND USE THEREOF AS ANTITUMOR AGENTS | LSI FINANCING 1 DESIGNATED ACTIVITY COMPANY (IE) | 2013-08-22 | — | — | US | disclosed |
| EP-2601185-A1 | DERIVATIVES OF PYRAZOLOPHENYL-BENZENESULFONAMIDE COMPOUNDS AND USE THEREOF AS ANTITUMOR AGENTS | Nerviano Medical Sciences S.r.l. (IT) | 2013-06-12 | — | — | EP | disclosed |
| CN-103153980-A | Derivatives of pyrazolophenylbenzenesulfonamide compounds and their use as antitumor agents | NERVIANO MEDICAL SCIENCES SRL | 2013-06-12 | — | — | CN | disclosed |
| WO-2012016993-A1 | DERIVATIVES OF PYRAZOLOPHENYL-BENZENESULFONAMIDE COMPOUNDS AND USE THEREOF AS ANTITUMOR AGENTS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217715-A1 | DERIVATIVES OF PYRAZOLOPHENYL-BENZENESULFONAMIDE COMPOUNDS AND USE THEREOF AS ANTITUMOR AGENTS | CDK2, CDK1, CDK4 | BRAF 8/4885MAPK3 109/4885MAPK1 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.